Who are CsA high dose's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sandimmune, CYCLOSPORINE, Tacrolimus capsule, CsA+MMF+CS, XR-tacrolimus QD + MMF BID then MMF QD, Tacrolimus, Accord.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/csa-high-dose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

CsA high dose — Competitive Intelligence Brief

CsA high dose (CsA high dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcineurin inhibitor. Area: Immunology.

phase 2 Calcineurin inhibitor Calcineurin Immunology Small molecule Live · refreshed every 30 min

Target snapshot

CsA high dose (CsA high dose) — Fovea Pharmaceuticals SA. Calcineurin inhibitor

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CsA high dose TARGET	CsA high dose	Fovea Pharmaceuticals SA	phase 2	Calcineurin inhibitor	Calcineurin
Sandimmune	cyclosporine	Novartis AG (originally Sandoz)	marketed	Calcineurin inhibitor (immunosuppressant)	Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2	1983-11-14
CYCLOSPORINE	CYCLOSPORINE		marketed	Calcineurin Inhibitor Immunosuppressant [EPC]	calcineurin	1983-01-01
Tacrolimus capsule	Tacrolimus capsule	Oslo University Hospital	marketed	Calcineurin inhibitor	Calcineurin (via FKBP12 binding)
CsA+MMF+CS	CsA+MMF+CS	Pfizer	marketed	Immunosuppressive combination therapy	Calcineurin (CsA); IMPDH type II (MMF); glucocorticoid receptor (CS)
XR-tacrolimus QD + MMF BID then MMF QD	XR-tacrolimus QD + MMF BID then MMF QD	University Hospital, Limoges	marketed	Calcineurin inhibitor + Antimetabolite immunosuppressant combination	Calcineurin (tacrolimus); Inosine monophosphate dehydrogenase (mycophenolate mofetil)
Tacrolimus, Accord	Tacrolimus, Accord	University of Cincinnati	marketed	Calcineurin inhibitor	Calcineurin (via FKBP12 binding)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-11-03 — Sandimmune · 8298568 · Formulation · US
2029-06-02 — Sandimmune · 9132071 · Formulation · US
2030-12-13 — Sandimmune · 8614178 · Formulation · US
2031-02-25 — Sandimmune · 8292129 · Formulation · US
2032-04-16 — Sandimmune · 8561859 · Formulation · US
2033-08-23 — Sandimmune · 8980839 · Formulation · US
2033-08-23 — Sandimmune · 10441630 · Formulation · US
2033-08-23 — Sandimmune · 9937225 · Formulation · US
2034-02-07 — Sandimmune · 9676525 · Formulation · US
2034-05-11 — Sandimmune · 9669974 · Formulation · US
2036-09-29 — Sandimmune · 12496326 · Method of Use · US
2037-02-28 — Sandimmune · 11951153 · Method of Use · US
2037-02-28 — Sandimmune · 10918694 · Formulation · US
2037-09-22 — Sandimmune · 10813976 · Formulation · US
2038-11-20 — Sandimmune · 11154513 · Formulation · US
2039-10-11 — Sandimmune · 11413323 · Method of Use · US
2042-04-01 — Sandimmune · 12059449 · Formulation · US

Sponsor landscape (Calcineurin inhibitor class)

Novartis · 4 drugs in this class
Astellas Pharma Inc · 4 drugs in this class
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. · 4 drugs in this class
University of Cincinnati · 3 drugs in this class
Allergan · 3 drugs in this class
Astellas Pharma China, Inc. · 3 drugs in this class
Novaliq GmbH · 3 drugs in this class
Hoffmann-La Roche · 3 drugs in this class
LEO Pharma · 3 drugs in this class
Santen SAS · 3 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CsA high dose — Competitive Intelligence Brief. https://druglandscape.com/ci/csa-high-dose. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab